Corcept Therapeutics CFO Atabak Mokari disposes of 40,000 common shares for $3.52 million

• Corcept Therapeutics CFO Atabak Mokari exercised stock options on July 15, 2026, acquiring 40,000 common shares at $19.26 to $23.06.
• He sold 40,000 common shares the same day at weighted-average prices of $86.78 to $89.43.
• His direct common stock holdings fell to 16,130 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-308058), on July 17, 2026, and is solely responsible for the information contained therein.